Oncology
Non-Small Cell Carcinoma
2
Pipeline Programs↗
2
Active Trials↗
3
Companies Involved↗
Non-small Cell Carcinoma is an early-stage landscape with 2 programs across 3 companies. The most active players are Pfizer, Merck & Co., Hellenic Cooperative Oncology Group.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
2programs
Small molecule150%
Monoclonal antibody150%
Modality classified for 100% of 2 pipeline programs.
Analysis
Trial Status
3
clinical trials
Recruiting1 · 33%
Completed1 · 33%
Active, not recruiting1 · 33%
Clinical Trials
Trial Activity
Characterization of Multi-Omics Landscapes in Long-Term Survival Following Immunotherapy and Development of an AI Pathological Prediction Model for Long-Term Survival Based on H&E-Stained Images in Advanced Non-Small Cell Lung Cancer
Recruiting·CCancer Institute and Hospital, Chinese Academy of Medical Sciences·N/A·NCT07668037·600 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)